Chiaroscuro hematopoietic stem cell.

P. Quesenberry, M. Habibian, M. Dooner, S. Zhong, J. Reilly, S. Peters, P. Becker, C. Grimaldi, J. Carlson, P. Reddy, S. Nilsson, F. M. Stewart

Research output: Chapter in Book/Report/Conference proceedingConference PaperResearchpeer-review


These observations suggest several immediate clinical strategies. In gene therapy, approaches could be targeted to obtain cycling of hematopoietic stem cells and gene-carrying retrovirus vector integration followed by engraftment at an appropriate time interval which favors engraftment. The same type of approach can be utilized for stem cell expansion approaches. Alternatively marrow or peripheral stem cell engraftment can be obtained with minimal to no toxicity in allochimeric strategies in such diseases as sickle cell anemia or thalassemia. A similar approach could be useful in obtaining cell engraftment with minimal toxicity in therapies employing cellular immune (T-cell and NK-cell) attack against cancer. These areas of clinical application are outline in Table 3.

Original languageEnglish
Title of host publicationOne Hundred Tenth Meeting of the American Clinical and Climatological Association
Number of pages8
Publication statusPublished - 1998
Externally publishedYes
EventAmerican Clinical and Climatological Association Meeting 1997 - Williamsburg, United States of America
Duration: 19 Oct 199722 Oct 1997
Conference number: 110th

Publication series

NameTransactions of the American Clinical and Climatological Association
ISSN (Print)0065-7778


ConferenceAmerican Clinical and Climatological Association Meeting 1997
Country/TerritoryUnited States of America

Cite this